At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Lenalidomide for Hodgkin Disease. Completed, enrolled 80 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedOct 2007
Primary CompletionSep 2016
TodayJul 2026
First PostedOct 5, 2007
Enrollment StartSep 6, 2007
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.0 yearsPosted 18.7 years ago
Interventions
Lenalidomidedrug